BOLTON SECURITIES CORPORATION’s BioCryst Pharmaceuticals BCRX Stock Holding History

BOLTON SECURITIES CORPORATION’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$9.5K	Buy	+1,000	New	+$7.77K	﹤0.01%	1628

Other funds holding BCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Deerfield Management New York $9.6B AUM 113.36% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

BOLTON SECURITIES CORPORATION's BCRX Position: Q1 2026 in Review

BOLTON SECURITIES CORPORATION opened a new position in BioCryst Pharmaceuticals (BCRX) in Q1 2026: 1,000 shares worth $9.5K. The stake represents ﹤0.01% of the portfolio and ranks #1628 among its holdings.

304 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

BOLTON SECURITIES CORPORATION held 1,000 shares of BioCryst Pharmaceuticals worth $9.5K as of Q1 2026.
BioCryst Pharmaceuticals was a new BOLTON SECURITIES CORPORATION position in Q1 2026.
BioCryst Pharmaceuticals made up ﹤0.01% of BOLTON SECURITIES CORPORATION's portfolio in Q1 2026, its #1628 holding.
304 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on BOLTON SECURITIES CORPORATION's 13F filing for Q1 2026, filed 12 Nov 2026.